Bill Would Ease FDA’s Social Media Rules for Drugmakers
July 7, 2015 in News
According to a release, drugmakers currently cannot share information about products via online platforms with a link to more detailed information about risks and benefits without fear of legal repercussions (Snyder Bulik, FiercePharmaMarketing, 6/30).
Overall, the bill aims to facilitate the meaningful use of the Internet, including social media websites, to share accurate information about medical products.
Specifically, the bill would:
- Allow drugmakers to share product information, such as the name and approved uses, online in character-limited platforms, such as Twitter (HR 2479 text, 5/20); and
- Lift FDA’s restrictions on the use of hyperlinks to indicate drug benefits and risks.
In a release, Long said, “This bill would simply push FDA to update its regulatory approach to communications to keep up with today’s technology.” He added, “FDA uses Twitter to link its announcements to more comprehensive information … My bill will allow the companies, which know their products best, to state introductory information with a link to more details, just like the FDA does” (Long release, June 2015).
The bill is now in the House Energy and Commerce Subcommittee on Health (FiercePharmaMarketing, 6/30).